Ann: PTX strategic collaboration with MD Anderson Cancer Center, page-23

I read the release again. "These binders are T cell receptor (TCR)-like". I see it's for blood cancers only at the moment and very new tech, but it feels like this is very significant. If can be extend this to solids as well (and works), it feel like the combination could truely gamechanger.

Maybe some of the more scientifically inclined can elaborate more on the significance of having the ability to create binders that are TCR-like, but from what I understand, this is very significant in addressing a CAR-T antigen targeting limitations. When you add this to what Omnicar is potentially capable of, i'm pretty excited to see how this unfolds.

New tech and early days but ..... very comfortable with that announcement.